Abstract Submission Deadline: December 15, 2024 at 6:00pm CET
All those interested in presenting abstracts at the congress are invited to submit their work to the Program Committee for review. Selected abstracts will be chosen for an oral presentation during the free communications sessions or as posters at the poster exhibition.
Please note: The acceptance of an abstract does not include the congress registration. Authors must be registered for the congress until February 14, 2025 in order to present their work.
Important deadlines:
December 15, 2024 (6:00pm CET) | Deadline for abstract submission |
January 30, 2025 | Notification of acceptance of abstracts |
January 31, 2025 | Start of Late-breaking & trials in progress abstract submission (until February 6, 2025) |
February 13, 2025 | Late-breaking & trials in progress notification of acceptance |
February 13, 2025 | Registration deadline for authors who wish to present their abstract at the Congress |
October 15, 2025 | End of on-demand service |
Patient Privacy / Clinical Photography
Photographs should at all times protect the privacy and identity of the subject. Eyes should be blacked out. The source of the photographs must also be declared if not the property of the presenter. This is to prevent the use of photographic material without permission.
Oral Presentations
Selected abstracts will be chosen for an oral presentation during the free communications sessions.
Poster Presentation
Abstracts selected for posters will be presented as posters at the poster exhibition during the congress.
Instructions for Preparation of the Poster:
The suggested dimension for your poster is DIN A0 (approx. 84 cm wide x 119 cm high), portrait format, in English language. Please allocate the top of the poster for the title and author's names and affiliations as stated in the submitted abstract.
Publication
All accepted abstracts will be published in the digital Book of Abstracts which will be available for download on the congress website and in the European Cancer Journal (ECJ).